AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15646945 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual brushing and daily flossing
Number of subjects: 47
Study 15646945 — intervention group
Group type: COMPARATOR
Intervention: Manual brushing only
Number of subjects: 47
Study 15646945 — intervention group
Group type: COMPARATOR
Intervention: Rotational oscillation brushing
Number of subjects: 47
Study 15646945 — intervention group
Group type: COMPARATOR
Intervention: Electric brushing using a rotational oscillation toothbrush
Number of subjects: 47
Study 15646945 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric brushing using a sonic toothbrush
Number of subjects: 47
Study 11298072 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy intervention involving development of professional relationships, nurse education on medication issues, and individualized medication reviews
Number of subjects: 3230
Study 11298072 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care in nursing homes)
Number of subjects: 3230
Study 10471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis for pregnant women
Number of subjects: 0
Study 7592245 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients
Number of subjects: 15
Study 7592245 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 15
Study 2547139 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg piperazine oestrone sulphate/day
Number of subjects: 7
Study 2547139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol/day
Number of subjects: 7
Study 2547139 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg oestradiol valerate/day
Number of subjects: 7
Study 2547139 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg oestriol/day
Number of subjects: 7
Study 2547139 — intervention group
Group type: COMPARATOR
Intervention: Combination with levonorgestrel (LNG) 250 micrograms/day
Number of subjects: 7
Study 1252278 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0
Study 31599031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related genes identified and characterized from P. puparum genome and transcriptome databases.
Number of subjects: 0
Study 31599031 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of immune-related genes from seven insect species.
Number of subjects: 0
Study 31599031 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental expression profiles of immune genes verified by quantitative polymerase chain reaction.
Number of subjects: 0
Study 31839957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day low-fibre diet
Number of subjects: 412
Study 31839957 — intervention group
Group type: COMPARATOR
Intervention: 1-day low-fibre diet
Number of subjects: 412
Study 27190095 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-A9-coated stent (BA9-DCS)
Number of subjects: 659
Study 27190095 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 659
Study 26093636 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 750
Study 26093636 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS enhanced with cognitive remediation and work-related social skills training
Number of subjects: 750
Study 26093636 — intervention group
Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 750
Study 23187043 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported progressive high‐intensity locomotor training (8-week program, 3 × 1h/week)
Number of subjects: 13
Study 20889387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Number of subjects: 0
Study 20889387 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 20889387 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin injection
Number of subjects: 0
Study 19084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide 0.33 microg kg(‐1)h(‐1) infusion
Number of subjects: 44
Study 19084439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19084439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide
Number of subjects: 44
Study 16798161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Tube (VT) method
Number of subjects: 64
Study 16798161 — intervention group
Group type: COMPARATOR
Intervention: Syringe Needle (SN) method
Number of subjects: 64
Study 12548313 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated spread with 2 g of plant sterols
Number of subjects: 50
Study 12548313 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated spread without plant sterols
Number of subjects: 50
Study 11853616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 128
Study 11853616 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 128
Study 9316514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by additional balloon angioplasty
Number of subjects: 50
Study 9316514 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty alone
Number of subjects: 50
Study 8296077 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day (n = 27)
Number of subjects: 56
Study 8296077 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg/day (n = 29)
Number of subjects: 56
Study 3570053 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone (1000 cGy whole pelvis, additional 4000 cGy to the parametria, two intracavitary insertions for 7500 mgh)
Number of subjects: 118
Study 3570053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation and surgery (2000 cGy whole pelvis, one intracavitary insertion for 5000-6000 mgh followed by radical hysterectomy)
Number of subjects: 118
Study 3570053 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 118
Study 3570053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation and surgery
Number of subjects: 118
Study 31267688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered intraocular injections
Number of subjects: 342
Study 31267688 — intervention group
Group type: COMPARATOR
Intervention: Physician-administered intraocular injections
Number of subjects: 342
Study 31267688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered injections
Number of subjects: 342
Study 31267688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 342
Study 30372645 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) contraceptive implant
Number of subjects: 103
Study 30372645 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 103
Study 27498280 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography using start systolic index (SSI)
Number of subjects: 125
Study 27498280 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle-tracking echocardiography using peak longitudinal displacement (PLD)
Number of subjects: 125
Study 27498280 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of apical rocking (AR) by expert readers
Number of subjects: 125
Study 27498280 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of apical rocking (AR) by novice readers
Number of subjects: 125
Study 24835329 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents
Number of subjects: 82
Study 24835329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 82
Study 24835329 — intervention group
Group type: COMPARATOR
Intervention: Embedded struts
Number of subjects: 82
Study 24835329 — intervention group
Group type: COMPARATOR
Intervention: Struts with tissue prolapse
Number of subjects: 82
Study 22403884 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted navigation (navigation group)
Number of subjects: 92
Study 22403884 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (traditional group)
Number of subjects: 92
Study 20624648 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type varicella zoster virus infection (WTVZV)
Number of subjects: 678
Study 20624648 — intervention group
Group type: EXPERIMENTAL
Intervention: WTVZV infection at age 0 to 8 years
Number of subjects: 678
Study 20624648 — intervention group
Group type: EXPERIMENTAL
Intervention: WTVZV infection at age 8 to 18 years
Number of subjects: 678
Study 20624648 — intervention group
Group type: EXPERIMENTAL
Intervention: WTVZV
Number of subjects: 678
Study 18248651 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening GH and/or morning hydrocortisone treatment
Number of subjects: 20
Study 18248651 — intervention group
Group type: COMPARATOR
Intervention: Omission of evening GH and/or morning hydrocortisone treatment
Number of subjects: 20
Study 18248651 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with GH
Number of subjects: 20
Study 18248651 — intervention group
Group type: COMPARATOR
Intervention: Omission of GH treatment
Number of subjects: 20
Study 18248651 — intervention group
Group type: COMPARATOR
Intervention: Omission of GH treatment in PHDC+ patients
Number of subjects: 20
Study 18248651 — intervention group
Group type: COMPARATOR
Intervention: Omission of GH treatment in patients with PHDC-
Number of subjects: 20
Study 18248651 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment and meals omission
Number of subjects: 20
Study 18248651 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 20
Study 18248651 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI and young age
Number of subjects: 20
Study 15684164 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 mug vaginally every 6 hours, most frequent regimen)
Number of subjects: 101
Study 15684164 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (in women with prior cesarean delivery)
Number of subjects: 101
Study 12352923 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 37
Study 12352923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic allograft nephropathy
Number of subjects: 37
Study 12352923 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of human herpesvirus 6 DNA
Number of subjects: 37
Study 10473080 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (CPT‐11; 200 mg/m2) as a 90‐min i.v. infusion followed by cisplatin (CDDP; 80 mg/m2) as a 3‐h i.v. infusion
Number of subjects: 11
Study 10473080 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (CPT‐11)
Number of subjects: 11
Study 10473080 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP)
Number of subjects: 11
Study 8904391 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nursing services
Number of subjects: 1223
Study 8904391 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health nursing services and physician contacts
Number of subjects: 1223
Study 8904391 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary approaches to prenatal care
Number of subjects: 1223
Study 1667474 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticalculus dentifrice containing 1.3% soluble pyrophosphate and 1.5% Gantrez copolymer in a 0.243% sodium fluoride/silica base
Number of subjects: 0
Study 1667474 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 0
Study 1667474 — intervention group
Group type: COMPARATOR
Intervention: Customary oral hygiene procedures
Number of subjects: 0
Study 7047469 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 6
Study 7047469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31273283 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil treatment
Number of subjects: 28
Study 31273283 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 28112575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical care group
Number of subjects: 320
Study 28112575 — intervention group
Group type: COMPARATOR
Intervention: International Warfarin Pharmacogenetic Consortium algorithm
Number of subjects: 320
Study 28112575 — intervention group
Group type: COMPARATOR
Intervention: Taiwan algorithm
Number of subjects: 320
Study 26100229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2, administered on day 1 every 21 days)
Number of subjects: 143
Study 26100229 — intervention group
Group type: COMPARATOR
Intervention: Volasertib with Pemetrexed
Number of subjects: 143
Study 26100229 — intervention group
Group type: COMPARATOR
Intervention: Volasertib (300 mg, administered on day 1 every 21 days)
Number of subjects: 143
Study 25146063 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and music therapy
Number of subjects: 24
Study 25146063 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (antidepressant drugs)
Number of subjects: 24
Study 21148540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear bone marrow cells (n = 69)
Number of subjects: 200
Study 21148540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear peripheral blood cells (n = 66)
Number of subjects: 200
Study 21148540 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 65)
Number of subjects: 200
Study 19300145 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration botulinum toxin A (100 U/ml)
Number of subjects: 16
Study 19300145 — intervention group
Group type: COMPARATOR
Intervention: Low concentration botulinum toxin A (10 U/ml)
Number of subjects: 16
Study 17913697 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting A (70/65 bpm)
Number of subjects: 99
Study 17913697 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting B (70/Off)
Number of subjects: 99
Study 17913697 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting C (80/65 bpm)
Number of subjects: 99
Study 17913697 — intervention group
Group type: COMPARATOR
Intervention: Baseline pacing (60 bpm/Off)
Number of subjects: 99
Study 14988255 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 50
Study 14988255 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal and glucose alone
Number of subjects: 50
Study 14988255 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal plus glucose
Number of subjects: 50
Study 11672451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training
Number of subjects: 32
Study 11672451 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 32
Study 9133941 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin 200 IU daily
Number of subjects: 31
Study 9133941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8265106 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 43
Study 8265106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3631942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg)
Number of subjects: 6
Study 3631942 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 6
Study 30817543 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (96%) solution
Number of subjects: 30
Study 30817543 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (80 mg) solution
Number of subjects: 30
Study 30817543 — intervention group
Group type: COMPARATOR
Intervention: Formalin solution
Number of subjects: 30
Study 30817543 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%) solution
Number of subjects: 30
Study 30817543 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin sodium (Cezol 1gr) solution
Number of subjects: 30
Study 29664109 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced fluid removal (using furosemide and/or continuous renal replacement therapy)
Number of subjects: 23
Study 29664109 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 23
Study 26336807 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Reminiscence Intervention (IRI)
Number of subjects: 60
Study 23988273 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and escitalopram (SSRIs) for 10 days
Number of subjects: 17
Study 22624605 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cathodal PPC stimulation
Number of subjects: 30
Study 22624605 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal PPC stimulation
Number of subjects: 30
Study 22624605 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 22624605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 30
Study 21612045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic measures including oral cavity checkup, hygiene instruction, promotion of oral health, sealing of I permanent molar teeth
Number of subjects: 101
Study 18755727 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5-10 mg)
Number of subjects: 49
Study 18755727 — intervention group
Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 49
Study 15926109 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (3 microg/minute)
Number of subjects: 16
Study 15926109 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate (400 mg)
Number of subjects: 16
Study 15926109 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate (400 mg) + Aldosterone (3 microg/minute)
Number of subjects: 16
Study 15926109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12576812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network algorithm based on urine levels of nuclear matrix protein‐22, monocyte chemoattractant protein‐1 and urinary intercellular adhesion molecule-1
Number of subjects: 253
Study 12576812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network algorithm
Number of subjects: 253
Study 12576812 — intervention group
Group type: COMPARATOR
Intervention: Hematuria dipstick test
Number of subjects: 253
Study 12576812 — intervention group
Group type: COMPARATOR
Intervention: Atypical cytology
Number of subjects: 253
Study 10549685 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (300 mg/day)
Number of subjects: 51
Study 10549685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8784742 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 0.10% 22:6n‐3
Number of subjects: 16
Study 8784742 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 0.11% 22:6n‐3
Number of subjects: 16
Study 8784742 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 0.22% 22:6n‐3
Number of subjects: 16
Study 8784742 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 0.24% 22:6n‐3
Number of subjects: 16
Study 8784742 — intervention group
Group type: COMPARATOR
Intervention: Formula without 22:6n‐3
Number of subjects: 16
Study 8784742 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with 20% 18:2n‐6 and 2.4% 18:3n‐3
Number of subjects: 16
Study 8784742 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 16
Study 1899350 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (600 micrograms daily) with diclofenac (150 mg daily)
Number of subjects: 24
Study 1899350 — intervention group
Group type: COMPARATOR
Intervention: placebo with diclofenac (150 mg daily)
Number of subjects: 24
Study 6347119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluphenazine decanoate (1.25 to 5.0 mg/2 wk)
Number of subjects: 126
Study 6347119 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose fluphenazine decanoate (12.5 to 50.0 mg/2 wk)
Number of subjects: 126
Study 6347119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluphenazine decanoate
Number of subjects: 126
Study 31828896 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials studying devices with humanitarian device exemption (HDE)
Number of subjects: 48
Study 31828896 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials studying devices with experimental indications (EI)
Number of subjects: 48
Study 31828896 — intervention group
Group type: COMPARATOR
Intervention: Trials of FDA-approved devices
Number of subjects: 48
Study 31828896 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial quality
Number of subjects: 48
Study 31828896 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding source
Number of subjects: 48
Study 30107814 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual education plus an additional module on realistic expectations for long-term recovery (intervention group)
Number of subjects: 0
Study 30107814 — intervention group
Group type: COMPARATOR
Intervention: Usual pre-operative education (control group)
Number of subjects: 0
Study 27084853 — intervention group
Group type: EXPERIMENTAL
Intervention: Online decision aid providing general and test-specific information on cholesterol and diabetes self-testing.
Number of subjects: 1259
Study 27084853 — intervention group
Group type: COMPARATOR
Intervention: Limited information sheet (control condition).
Number of subjects: 1259
Study 24168874 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat group (githeri with meat)
Number of subjects: 12
Study 24168874 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk group (githeri plus whole milk)
Number of subjects: 12
Study 24168874 — intervention group
Group type: COMPARATOR
Intervention: Plain Githeri (githeri with added oil)
Number of subjects: 12
Study 24168874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention feeding)
Number of subjects: 12
Study 23088297 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber whole grain rye bread (RB)
Number of subjects: 33
Study 23088297 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread (WB)
Number of subjects: 33
Study 20558037 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score from cardiovascular therapy trial
Number of subjects: 0
Study 20558037 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary composite measure from cardiovascular therapy trial
Number of subjects: 0
Study 17131168 — intervention group
Group type: EXPERIMENTAL
Intervention: Water perfusion catheter
Number of subjects: 18